News
November 30, 2018
Selected to Dispense XOSPATA
Onco360 was selected as 1 of only 3 Specialty Pharmacy providers to dispense XOSPATA® (Gilteritinib) for the treatment of patients with relapsed or refractory FMS-like Tyrosine Kinase 3 (FLT3) mutation-positive acute myeloid leukemia (AML).
November 1, 2018
Dispensing Talzenna + Vizimpro
Talzenna® and Vizimpro® available now through Onco360 Oncology Specialty Pharmacy.
October 3, 2018
Exclusive Provider for Libtayo
Onco360 Selected as the Exclusive Specialty Pharmacy for Libtayo® (cemiplimab-rwlc) Limited Distribution Pharmacy Network.
July 2, 2018
Braftovi + Mektovi Available Now
Onco360 selected to participate in the limited distribution network for Array Biopharma’s new products BRAFTOVI™ (encorafenib) and MEKTOVI® (binimetinib) for the treatment of patients with unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation, as detected by an FDA-approved test.
March 22, 2018
Imbruvica New Formulation
Now Available From Onco360 - The New IMBRUVICA® pill is now available as a one pill, once a day treatment.
October 16, 2017
Selected for VERZENIO LD Network
Onco360 has been selected to participate in the limited distribution network for Eli Lilly's new product, VERZENIO (Abemaciclib)
August 1, 2017
NERLYNX Available From Onco360
Onco360 announces selection to highly limited pharmacy network for NERLYNX.
April 14, 2016
Venclexta Available From Onco360
Onco360 announces selection to highly limited pharmacy network for VENCLEXTA.
March 22, 2016
New Indication for Xalkori
Limited distribution medication XALKORI (crizotinib) receives approval for certain NSCLC patients.
March 7, 2016
Second Indication for Ibrance
Limited distribution breast cancer medication IBRANCE approved for additional indication.